Background {#Sec1}
==========

The incidence of intertrochanteric hip fracture, which accounts for 31--51% of proximal femoral fractures \[[@CR1]\], has increased during the last decade. Accompanied by physical deterioration, this type of fracture is prevalent among geriatric patients. Furthermore, most patients with this type of fracture experience medical comorbidities, which can worsen complications if left untreated. Consequently, early surgery is considered the best option for these patients by the majority of clinicians worldwide. The advantages of surgery include the restoration of anatomical alignment and early rehabilitation \[[@CR2]\]. Moreover, early surgery can reduce the risk of complications.

Fixation with dynamic hip screws (DHS) is generally considered the standard management option for treating these fractures and has gained extensive acceptance \[[@CR3], [@CR4]\]. However, various types of implants are available, including extramedullary and intramedullary devices. Consequently, the preferred treatment option remains controversial due to the lack of randomized controlled trials (RCTs) comparing these therapies. Accordingly, an analysis that integrates evidence of current on treatment options for intertrochanteric hip fracture is needed.

A traditional pairwise meta-analysis cannot simultaneously include various types of prevalent therapies. To identify the optimal treatment method, we compared all candidate therapies in the same analysis by performing a network of treatments meta-analysis involving a direct analysis and a combined analysis. We aimed to comprehensively integrate the current evidence regarding blood loss and operation time outcomes from operative interventions in patients with intertrochanteric fractures.

Materials and methods {#Sec2}
=====================

Search strategy {#Sec3}
---------------

EMBASE, MEDLINE, CNKI, and the Cochrane Library were searched. All searches were limited to RTCs involving humans. Searches were not limited by language, publication date, or publication status. We also reviewed the reference lists of all selected studies to identify any additional relevant articles. The searches incorporated the following keywords: "intertrochanteric fractures," "proximal femoral nail anti-rotation," "dynamic hip screw," "gamma nail," "percutaneous compression plate," and "artificial femoral head replacement."

Study selection {#Sec4}
---------------

Studies that satisfied the following inclusion criteria were eligible for the analysis: (1) RCTs involving human participants treated for intertrochanteric hip fractures; (2) evaluations including either surgical time or blood loss, with complete data; (3) patients aged over 18 years; (4) the highest-quality study or the most recent publication in cases where data were duplicated; (5) comparison of at least two of the five treatments studied (DHS, PFNA, GN, PCCP, FHR).

Data extraction and quality assessment {#Sec5}
--------------------------------------

The data were reviewed independently by two extractors. Extractors resolved any disagreements by consensus. The following details were extracted from each study: name of the first author, country of origin, sample size, year of publication, treatments compared, design, population characteristics, outcome measures, and fracture classification. The outcome measures of interest were surgical time and blood loss, as measured by change from baseline. The reviewers evaluated the methodological quality of all individual studies using the JADAD scale \[[@CR5]\]. Particularly, the reviewers assessed the procedures of randomization sequence generation, appropriate blinding, allocation concealment, and reporting of withdrawal.

Statistical analysis {#Sec6}
--------------------

Eligible trials comprising direct and indirect comparisons were summarized qualitatively. In addition, essential clinical outcomes and methodological variables were recorded. We performed a traditional "head-to-head" meta-analysis to calculate the pooled estimates of the standard mean difference (SMD) and 95% confidence intervals (CIs). We conducted the statistical analysis using Stata version 11.0 (Stata Corporation, College Station, TX, USA) and developed a DerSimonian-Laird random effects model for comparisons between two strategies \[[@CR6]\]. The Cochrane Q test and the *I*^2^ statistic were assessed to determine the effect of between-study heterogeneity \[[@CR7], [@CR8]\]. Begg's test was also conducted to investigate publication bias \[[@CR9]\].

We also performed a random effects Bayesian network meta-analysis to enhance the head-to-head meta-analysis. Using this method, all five treatments could be simultaneously considered. In addition, this method increases statistical power by merging both direct and indirect comparison evidence across all five interventions. Therefore, conclusions could be educed on the relative effectiveness of interventions, such as GN fixation and PCCP use, which have never before been directly compared.

The network meta-analyses were undertaken using Bayesian Markov chain Monte Carlo (MCMC) simulation methods with minimally informative prior distributions. Thousands of simulated iterations were run based on the data and description of the proposed distributions of relevant parameters in WinBUGS software (version 1.4.3. MRC Biostatistics Unite, Cambridge, UK) \[[@CR10]\]. The first 10,000 iterations (burn-in) were discarded, and 40,000 further iterations were run. Pooled effect sizes are reported as posterior medians of SMDs, and the corresponding 95% credible intervals (CrIs) were applied using the 2.5th and 97.5th percentiles of the posterior distribution, which can be interpreted similar to conventional 95% CIs \[[@CR11]\]. We also calculated the percentage contribution of each effect size in the evidence base, i.e., the probability that each treatment was the most effective therapy or the second most effective therapy, etc. The distribution of ranking probabilities is presented graphically.

Meta-regression analyses were conducted to evaluate whether the publication year and type of fractures could explain the latent heterogeneity. The inconsistency between direct and indirect comparisons was evaluated using the loop-specific method \[[@CR12]\]. This approach evaluates the difference (inconsistency factor) and 95% CI, between direct and indirect estimations for a specific comparison. Inconsistency was defined as disagreement between direct and indirect evidence with a 95% CI excluding 0.

Results {#Sec7}
=======

Eligible studies and characteristics {#Sec8}
------------------------------------

After reviewing all selected studies, 24 trials involving five treatments met the selection criteria \[[@CR13]--[@CR36]\]. A total of 3097 individuals with sufficient data were included in the quantitative synthesis (meta-analysis). The study selection process, including reasons for exclusion, is presented by a flowchart (Fig. [1](#Fig1){ref-type="fig"}). The characteristics of all involved studies are summarized in Table [1](#Tab1){ref-type="table"}. Figure [2](#Fig2){ref-type="fig"} shows all comparisons analyzed within the network. The study sample size varied from 60 to 426 participants, with a median sample size of 129. The mean age of patients varied from 62.2 to 83.6 years. According to the Evans or AO/OTA classification, all fractures were categorized as stable (Evans type I/II and AO/ATO type 31-A1) or unstable (Evans type III--V and AO/ATO type 31-A2/A3). In 7 trials, all selected patients had unstable fractures; in 15 trials, all selected patients had compound fractures, either stable or unstable. We conducted a quality assessment of all included studies (Table [2](#Tab2){ref-type="table"}) and found that the studies had a broad range of overall reporting quality. The proportions of studies with definite descriptions of randomization, allocation concealment, blinding, dropout, and intention-to-treat analysis were 83.33% (20/24), 70.83% (17/24), 62.5% (15/24), 87.5% (21/24), and 91.67% (22/24), respectively. According to meta-regression analyses, blood loss and operation time were not affected by differences across trials in terms of the publication year or type of fractures (Table [3](#Tab3){ref-type="table"}). No evidence of inconsistency between the direct and indirect estimates was observed in this meta-analysis (Table [4](#Tab4){ref-type="table"}). No publication bias was observed among the included studies (Table [5](#Tab5){ref-type="table"}).Fig. 1Flowchart of the study selection processTable 1Baseline characteristics of included studiesAuthor (year)CountryInterventionMean age (years)Patients (number)Type of fractures (unstable/stable)Tang 2009ChinaDHS, FHR80.7109109/0Verettas 2010GreeceDHS, GN80.1118118/0Zou 2009ChinaDHS, PFNA6512194/27Xu 2010ChinaDHS, PFNA78.2106106/0Wang 2010ChinaDHS, FHR83.56060/0Peyser 2007IsraelDHS, PCCP80.810360/22Ahrengart 2002SwedenDHS, GN80426222/204Xu 2010ChinaPFNA, GN76.710740/67Butt 1995UKDHS, GN78.59530/30Leung 1992ChinaDHS, GN79.618650/136Kosygan 2002EnglandDHS, PCCP82.810849/59Peter 1995CanadaDHS, GN80.110258/44Kukla 1997AustriaDHS, GN83.512054/66Yang 2011AmericaDHS, PCCP76.566NAHoffman 1996New ZealandDHS, GN80.96722/45Garg 2011IndiaDHS, PFNA62.28181/0Guo 2013ChinaPFNA, PCCP72.99049/41Brandt 2002NetherlandsDHS, PCCP80.97141/30Aktselis 2014GreeceDHS, GN837171/0Vaquero 2012SpainPFNA, GN83.66161/0Utrilla 2005SpainDHS, GN80.221054/156Goldhagen 1994AmericaDHS, GN7863NAChristopher 2001EnglandDHS, GN81400193/207Huang 2006ChinaDHS, FHR72.815643/113Fig. 2The eligible clinical trials included in the network meta-analysis. The width of the connecting lines is proportional to the number of available head-to-head (direct) comparisons. The size of each node is proportional to the number of randomly assigned participants (sample size)Table 2Methodological quality assessment by adjusted Jadad scaleAuthorRandom sequence generationAllocation concealmentBlinding of participantsDropout AddressedITTTang 2009UnclearUnclearUnclearAdequateYVerettas 2010AdequateUnclearUnclearAdequateYZou 2009InadequateUnclearUnclearUnclearYXu 2010AdequateAdequateAdequateAdequateYWang 2010InadequateUnclearUnclearUnclearNPeyser 2007AdequateAdequateAdequateAdequateYAhrengart 2002AdequateAdequateAdequateAdequateYXu 2010AdequateAdequateAdequateAdequateYButt 1995AdequateAdequateAdequateUnclearYLeung 1992AdequateAdequateInadequateAdequateYKosygan 2002AdequateAdequateAdequateAdequateYPeter 1995AdequateAdequateAdequateAdequateYKukla 1997AdequateAdequateAdequateAdequateYYang 2011AdequateAdequateAdequateAdequateYHoffman 1996AdequateAdequateAdequateAdequateYGarg 2011AdequateUnclearUnclearAdequateNGuo 2013AdequateAdequateUnclearAdequateYBrandt 2002AdequateAdequateAdequateAdequateYAktselis 2014InadequateUnclearUnclearAdequateYVaquero2012AdequateAdequateAdequateAdequateYUtrilla 2005AdequateAdequateAdequateAdequateYGoldhagen 1994AdequateUnclearUnclearUnclearYChristopherAdequateAdequateAdequateAdequateYHuang 2006AdequateAdequateAdequateAdequateY*ITT* intention-to-treat analysisTable 3Results of the meta-regressionOutcomeRegression coefficient(95%CI)Publication yearType of fracturesBlood loss− 0.02 (− 0.11, 0.08)− 0.70 (− 2.04, 0.64)Operation time− 0.32 (− 0.10, 0.04)− 0.22 (− 1.28, 0.83)Table 4Assessment of inconsistency between direct and indirect evidenceLoopBlood lossOperation timeInconsistency 95% CIInconsistency 95% CIDHS,PCCP, PFNA3.59 (0.00, 7.33)1.82 (0.00, 5.77)DHS, GN, PFNA2.66 (0.00, 4.77)0.71 (0.00, 2.71)Table 5Assessment of heterogeneity and publication bias for trials included indirect meta-analysesComparisonsNumberQ-test heterogeneity(*P*/*I*^2^)Begg's test (*p*)Blood loss DHS vs PFNA20.00/98.3%1.00 DHS vs GN70.01/66%0.76 DHS vs PCCP30.00/82.9%1.00 DHS vs FHR30.04/69.4%0.30 PFNA vs GN1NANA PFNA vs PCCP1NANAOperation time DHS vs PFNA30.00/98.8%0.30 DHS vs GN110.00/91.5%1.00 DHS vs PCCP40.00/92.9%0.73 DHS vs FHR30.00/91.4%1.00 PFNA vs GN20.63/0%1.00 PFNA vs PCCP1NANA*P* \< 0.05 indicates significant heterogeneity in Cochrane Q-test, publication bias in Begg's test. *NA* not applicable

Blood loss {#Sec9}
----------

The results of our network meta-analysis comparing the five treatments regarding the outcome of blood loss are reported in Table [6](#Tab6){ref-type="table"}. The outcome of five treatments ranked by the blood loss is also presented. Except for FHR, all interventions had greater effects on blood loss than DHS treatment. A relatively greater increase in blood loss was seen in DHS treatment than for PFNA (SMD 1.96; 95% CI, 1.014--1.963) or PCCP (SMD 1.26; 95% CI, 0.31--2.20) interventions (Table [6](#Tab6){ref-type="table"}). This finding indicated that the PFNA intervention leads to the least blood loss among the five treatments studied. PFNA intervention consistently showed the highest probability of having the superior ranking position among all approaches, and PCCP use showed the second highest probability (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Ranking probability curves for blood loss during the operation. The graph displays the distribution of probabilities for each treatment. The *X*-axis represents the rank, and the *Y*-axis represents probabilities. The ranking indicates the probability that a particular treatment is the "best," "second best," etcTable 6Results of the direct and indirect meta-analysesaDHS3.41(0.13, 6.70)0.17(− 0.04, 0.38)0.71(0.11, 1.31)− 0.19(− 0.61, 0.22)1.96(1.014, 1.963)PFNA− 0.43(− 0.81, − 0.04)0.93(0.50, 1.37)NA0.26(− 0.35, 0.87)− 1.70(− 2.74, − 0.66)GNNANA1.26(0.31, 2.20)− 0.70(− 1.87, 0.46)1.00(− 0.10, 2.09)PCCPNA− 0.23(− 1.26, 0.81)− 2.19(− 3.60, − 0.77)− 0.49(− 1.69, 0.71)− 1.49(− 2.90, − 0.08)FHRbDHS1.24(− 1.36, 3.84)0.21(− 0.12, 0.54)0.34(− 0.49, 1.16)− 0.12(− 0.92, 0.67)0.75(− 0.02, 0.75)PFNA− 0.30(− 0.60, 0.01)0.94(0.50, 1.37)NA0.25(− 0.26, 0.77)− 0.49(− 1.3, 0.33)GNNANA0.61(− 0.20, 1.44)− 0.14(− 1.16, 0.88)0.35(− 0.59, 1.32)PCCPNA− 0.12(− 1.15, 0.91)− 0.86(− 2.15, 0.42)− 0.37(− 1.52, 0.78)− 0.72(− 2.03, 0.59)FHRa Comparison of blood loss between 5 treatments. b Comparison of operation time between 5 treatments. Results of direct comparisons are listed in the upper triangle, and the estimation was calculated as the row-defining treatment compared with the column-defining treatment. Results of network meta-analysis are listed in the lower triangle, and the estimation was calculated as the column-defining treatment compared with the row-defining treatment

Operation time {#Sec10}
--------------

Table [6](#Tab6){ref-type="table"} shows the results of the network meta-analysis on the outcome of operation time. Except for FHR, all interventions had greater effects on operation time than DHS treatment. A relatively longer operation time was observed for DHS than for PFNA (SMD 0.75; 95% CI, − 0.02--0.75) or PCCP (SMD 0.61; 95% CI, − 0.20--1.44) interventions. A significantly shorter duration was observed for the PFNA approach than for GN (SMD − 0.49; 95% CI, − 1.3--0.33), or FHR use (SMD − 0.86; 95% CI, − 2.15--0.42). Therefore, PFNA, PCCP, and GN interventions resulted in significantly greater decreases in operation time. Figure [4](#Fig4){ref-type="fig"} shows that among the five treatments, PFNA treatment exhibited the highest probability of reducing the operation time, and PCCP treatment had the second highest probability.Fig. 4Ranking probability curves for operation time. The graph displays the distribution of probabilities for each treatment. The *X*-axis represents the rank, and the *Y*-axis represents probabilities. The ranking indicates the probability that a particular treatment is the "best," "second best," etc

Discussion {#Sec11}
==========

This network meta-analysis reviewed existing evidence for the treatment of intertrochanteric hip fractures, with the aim to synthesize the evidence and to confirm decision-making in the absence of direct comparisons. Almost all previous RCTs or meta-analysis studies were evaluations of direct comparisons among DHS, GN, PFNA, and PCCP approaches. Few studies compared FHR with these treatments. Our findings integrate these previous comparisons.

With the rapid increase in the aging population, intertrochanteric hip fractures have shown an increasing trend. This type of fracture is a worldwide health problem, leading to serious medical consequences that interfere with quality of life and mortality \[[@CR37]\]. During the past decades, this type of fracture has resulted in increased economic burden and has led to increased consumption of health care resources \[[@CR38]\]. Nevertheless, considerable debate and controversy still exist regarding the optimal method and device for fixation of intertrochanteric fractures.

The DHS, which is an extramedullary fixation device, has previously been considered the gold standard treatment for intertrochanteric fractures \[[@CR39]\]. However, this intervention, although technically simpler, requires a considerable amount of exposure and ambient soft tissue stripping, which can lead to heavy bleeding \[[@CR40]\]. The disadvantages of traditional internal fixation, such as increased blood loss, postoperative pain, and slow function recovery, led to the emergence of a minimally invasive surgical option as an alternative treatment technique \[[@CR41]\]. PCCP is a new type of minimally invasive surgical device. It consists of a biaxial, two parallel femoral neck screws, and three cortical screws. We can insert the screws through two 2-cm incisions percutaneously. Compared with DHS implants, it can reduce the damage of the lateral cortex and lateral femoral muscles. GN is an intramedullary implant with a short lever arm and a small bending moment. Compared with DHS implants, this implant has two advantages: The relatively semi-closed operation through a small incision does not require exposure of the fracture site; in addition, sliding screws can generate pressure on the proximal medial cortex to increase the stability of internal plants and fracture site. Therefore, inserting GN nails helps to reduce blood loss and shorten the operation time. PFNA intervention involves an innovative implant developed by the AO/ASIF group that is based on a proximal femoral nail (PFN) with a special helical blade. We found that PFNA treatment leads to the lowest amount of blood loss and the shortest operation time among the five treatments.

After PFNA, the amount of blood loss for each method ranked in the following increasing order: PCCP, GN, FHR, and DHS. Less blood loss during an operation leads to fewer incidences of allogenic blood and reduces potential risks of transfusion reactions, disease transmission and immunomodulation \[[@CR42]--[@CR44]\]. The risk of a serious or fatal transfusion-transmitted disease is approximately 3 in 10,000, while the chance of a minor allogenic reaction is 1 in 100 \[[@CR42]\]. Regarding the reduction in operation time, PFNA treatment was also ranked as the top intervention. A shorter surgical time reduces the risk of minor or major anesthesia problems and blood loss, which helps to prevent the occurrence of anemia and hypoalbuminemia and improves patient recovery. Additionally, from a mechanical point of view, adequate evidence has demonstrated the superiority of the helical blade over a sliding hip screw for head stabilization and fragment sliding. The distinctive design consists of a large surface and an incremental core diameter, assuring maximum compaction and optimal hold in the bone. Because the PFNA blade can induce compaction of cortical bone, the increased rotational and angular stability can resist rotation and varus collapse of the head, as shown in cadaveric studies \[[@CR45]\]. Therefore, PFNA, one type of modified minimally invasive implant technique used for internal fixation in elderly patients, is generally accepted in modern treatment of orthopedic trauma \[[@CR46], [@CR47]\].

The advantages of our analysis are that we simultaneously compared more than two treatments in the same analysis and provided relative effect estimates for all treatment comparisons, even for those that have not been directly compared before; thus, for each treatment, we estimated the probability that the given treatment is optimal. However, there are several limitations of our network meta-analyses that need to be acknowledged. First, we only analyzed total blood loss and surgical time because these were the most frequently reported outcomes in all included studies. However, many other outcomes should be considered, such as postoperative functional status, radiation time, complication rate, and fixation failure. Additional clinical trials and longitudinal studies with these outcomes may be reported in the future, enabling similar analyses. Second, statistical heterogeneity was moderate; however, most comparisons had wide 95% CIs and included values that indicated very high or no heterogeneity. Existing uncertainties regarding the potential heterogeneity of these studies should be explored.

Conclusion {#Sec12}
==========

In conclusion, PFNA is biomechanically and biologically superior to other implant techniques for treating intertrochanteric hip fractures. It provides stable intramedullary fixation to resist varus collapse, leading to the lowest amount of blood loss and the shortest operation time.
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